Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADTXNASDAQ:HSTONASDAQ:INMNASDAQ:RVLP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$1.33-14.7%$1.73$1.28▼$27,200.00$2.82M1.49890,420 shs716,206 shsHSTOHistogen$0.01-43.5%$0.02$0.05▼$0.55$43K1.1910,369 shs1,050 shsINMInMed Pharmaceuticals$3.38-2.3%$2.86$1.72▼$15.70$4.08M0.171.01 million shs250,562 shsRVLPRVL Pharmaceuticals$0.04$0.03▼$1.91N/AN/AN/A63.96 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt-14.74%0.00%-21.30%-73.40%-99.99%HSTOHistogen0.00%+4,325.00%-34.44%-36.79%-94.10%INMInMed Pharmaceuticals-2.31%+35.74%+28.52%+64.08%-35.74%RVLPRVL Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADTXAditxtN/AN/AN/AN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/AINMInMed Pharmaceuticals1.0102 of 5 stars0.05.00.00.02.40.00.6RVLPRVL PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADTXAditxt 0.00N/AN/AN/AHSTOHistogen 0.00N/AN/AN/AINMInMed Pharmaceuticals 0.00N/AN/AN/ARVLPRVL Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADTXAditxt$130K21.69N/AN/A($1.52) per share-0.88HSTOHistogen$19K2.25N/AN/A$3.13 per share0.00INMInMed Pharmaceuticals$4.60M0.89N/AN/A$20.64 per share0.16RVLPRVL Pharmaceuticals$49.72M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADTXAditxt-$34.45MN/A0.00∞N/A-46,082.47%-389.10%-84.71%8/18/2025 (Estimated)HSTOHistogen-$10.62M-$2.81N/A∞N/AN/AN/AN/AN/AINMInMed Pharmaceuticals-$7.68M-$12.09N/A∞N/A-168.87%-107.93%-82.97%N/ARVLPRVL Pharmaceuticals-$51.69MN/A0.00N/AN/AN/AN/AN/AN/ALatest RVLP, INM, HSTO, and ADTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ADTXAditxt-$26,400.00-$8.12+$26,391.88-$8.12$0.43 million$0.00 million5/12/2025Q3 2025INMInMed PharmaceuticalsN/A-$1.94N/A-$1.94N/A$1.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADTXAditxtN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/ARVLPRVL PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADTXAditxtN/A0.080.08HSTOHistogenN/AN/AN/AINMInMed Pharmaceuticals0.063.493.04RVLPRVL PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADTXAditxt15.54%HSTOHistogenN/AINMInMed Pharmaceuticals20.12%RVLPRVL Pharmaceuticals14.36%Insider OwnershipCompanyInsider OwnershipADTXAditxt0.01%HSTOHistogen3.30%INMInMed Pharmaceuticals1.43%RVLPRVL Pharmaceuticals4.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADTXAditxt602.12 million2.12 millionNo DataHSTOHistogen204.27 millionN/ANot OptionableINMInMed Pharmaceuticals101.21 million1.19 millionNot OptionableRVLPRVL Pharmaceuticals125111.41 million106.50 millionOptionableRVLP, INM, HSTO, and ADTX HeadlinesRecent News About These CompaniesUnravel Biosciences Receives FDA Orphan Drug Designation for Vorinostat (RVL-001) as a Treatment for Rett SyndromeMay 28, 2024 | tmcnet.comRaval ICS Ltd.May 17, 2024 | wsj.comRVLPQ RVL Pharmaceuticals plcMarch 2, 2024 | seekingalpha.comRVL Pharmaceuticals PLC RVLPQJanuary 11, 2024 | morningstar.comMRVL Pharmaceuticals plc’s latest rating changes from various analystsOctober 18, 2023 | knoxdaily.comKRVL Pharmaceuticals Shares Plummet 50% as Subsidiaries File For BankruptcyOctober 13, 2023 | marketwatch.comSpecialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 12, 2023 | benzinga.comRVL Subsidiaries To Effectuate Change Of Control; RVLP Ordinary Shares Expected To Be CancelledOctober 12, 2023 | markets.businessinsider.comRVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 12, 2023 | finance.yahoo.comRVL Pharmaceuticals plc [RVLP] Investment Guide: What You Need to KnowOctober 11, 2023 | knoxdaily.comKWhy Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?October 6, 2023 | investorplace.comInvesting in RVL Pharmaceuticals plc [RVLP]: What You Must KnowOctober 4, 2023 | knoxdaily.comKUnderstanding the Risks of Investing in RVL Pharmaceuticals plc (RVLP)September 27, 2023 | knoxdaily.comKRVLP Shares Experience Surge in ValueSeptember 21, 2023 | knoxdaily.comKExamining the Potential Price Growth of RVL Pharmaceuticals plc (RVLP)September 13, 2023 | knoxdaily.comKAnalysts predict RVLP shares will perform strongly in 2023September 7, 2023 | knoxdaily.comKRVL Pharmaceuticals plc [RVLP] Investment Appeal on the RiseAugust 23, 2023 | knoxdaily.comKUnmasking the Value Trap: A Deep Dive into RVL Pharmaceuticals PLCAugust 23, 2023 | finance.yahoo.comRVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | finance.yahoo.comRVL Pharmaceuticals (RVLP) Gets a Buy from H.C. WainwrightAugust 21, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVLP, INM, HSTO, and ADTX Company DescriptionsAditxt NASDAQ:ADTX$1.33 -0.23 (-14.74%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.34 +0.01 (+0.75%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Histogen NASDAQ:HSTO$0.01 -0.01 (-43.50%) As of 06/27/2025Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.InMed Pharmaceuticals NASDAQ:INM$3.38 -0.08 (-2.31%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.32 -0.06 (-1.75%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.RVL Pharmaceuticals NASDAQ:RVLPRVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
